新辅助抗PD-1(特瑞普利单抗)联合阿昔替尼治疗可切除黏膜黑色素瘤的II期临床试验
这项单臂II期试验入组29例可切除黏膜黑色素瘤患者,接受特瑞普利单抗联合阿昔替尼新辅助治疗8周后手术,主要终点病理缓解率为33.3%(8/24),中位无事件生存期11.1个月,联合治疗耐受性可。
要点
- 新辅助特瑞普利单抗联合阿昔替尼的病理缓解率为33.3%(8/24),含4例病理完全缓解和4例病理部分缓解。
- 中位随访34.2个月,全组中位无事件生存期11.1个月,中位总生存期未达到。
- 新辅助治疗后CD3+和CD3+CD8+肿瘤浸润淋巴细胞显著增加,尤其在病理缓解者中。
核心结论
- 新辅助特瑞普利单抗联合阿昔替尼在可切除黏膜黑色素瘤中显示出有前景的病理缓解率,且治疗后浸润性CD3+和CD3+CD8+ T细胞显著增加。
研究设计与样本
- 单臂II期临床试验,2019年8月至2021年10月入组29例可切除黏膜黑色素瘤患者并接受治疗,其中24例接受切除。
- 患者接受特瑞普利单抗3 mg/kg每2周一次联合阿昔替尼5 mg每日两次新辅助治疗8周,术后2±1周开始辅助特瑞普利单抗3 mg/kg每2周一次共44周。
- 主要终点为根据国际新辅助黑色素瘤联盟推荐的病理缓解率。
主要发现
- 病理缓解率为33.3%(8/24;4例病理完全缓解和4例病理部分缓解)。
- 全组中位无事件生存期为11.1个月(95%CI 5.3-16.9个月),中位总生存期未达到。
- 新辅助治疗耐受性可,发生8例(27.5%)3-4级治疗相关不良事件,无治疗相关死亡。
- 17例患者基线和术后组织样本(5例缓解者和12例非缓解者)的多重免疫组化显示,新辅助治疗后CD3+(P=0.0032)和CD3+CD8+(P=0.0038)肿瘤浸润淋巴细胞显著增加,尤其在病理缓解者中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The outcome of patients with resectable mucosal melanoma is poor. Toripalimab combined with axitinib has shown impressive results in metastatic mucosal melanoma with an objective response rate of 48.3% and a median progression-free survival of 7.5 months in a phase Ib trial. It was hypothesized that this combination administered in the neoadjuvant setting might induce a pathologic response in resectable mucosal melanoma, so we conducted this trial. PATIENTS AND METHODS: This single-arm phase II trial enrolled patients with resectable mucosal melanoma. Patients received toripalimab 3 mg/kg once every 2 weeks (Q2W) plus axitinib 5 mg two times a day (b.i.d.) for 8 weeks as neoadjuvant therapy, then surgery and adjuvant toripalimab 3 mg/kg Q2W starting 2 ± 1weeks after surgery for 44 weeks. The primary endpoint was the pathologic response rate according to the International Neoadjuvant Melanoma Consortium recommendations. RESULTS: Between August 2019 and October 2021, 29 patients were enrolled and received treatment, of whom 24 underwent resection. The median follow-up time was 34.2 months (95% confidence interval 20.4-48.0 months). The pathologic response rate was 33.3% (8/24; 4 pathological complete responses and 4 pathological partial responses). The median event-free survival for all patients was 11.1 months (95% confidence interval 5.3-16.9 months). The median overall survival was not reached. Neoadjuvant therapy was tolerable with 8 (27.5%) grade 3-4 treatment-related adverse events and no treatment-related deaths. Tissue samples of 17 patients at baseline and after surgery were collected (5 responders and 12 nonresponders). Multiplex immunohistochemistry demonstrated a significant increase in CD3+ (P = 0.0032) and CD3+CD8+ (P = 0.0038) tumor-infiltrating lymphocytes after neoadjuvant therapy, particularly in pathological responders. CONCLUSIONS: Neoadjuvant toripalimab combined with axitinib in resectable mucosal melanoma demonstrated a promising pathologic response rate with significantly increased infiltrating CD3+ and CD3+CD8+ T cells after therapy.
引用
- Lian B, Li Z, Wu N, et al. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Ann Oncol. 2023. PMID: 37956739. doi:10.1016/j.annonc.2023.10.793
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。